Author: admin

A muscle-tissue engineering company is set to highlight the steps being taken to ease the path of regenerative therapies into commercial manufacturing. Muvon Therapeutics, a clinical-stage company working on regenerative treatments for weakened/damaged muscle and tissue, says key challenges have included co-developing regulations, automation of manufacturing, and hiring experienced personnel. “There’s a translation gap when you’re bringing a novel therapy from academia into industry,” explains Deana Mohr, PhD, CEO, and co-founder. “Startups need to hit a moving target [on drug regulation] because regulatory frameworks are still maturing.” One of the early key challenges for Muvon, Mohr says, was finding experienced…

Novo Nordisk’s new partnership with Bob Langer-founded Vivtex aims to turn injectable obesity drugs into pills. How people deal with obesity care may not arrive with a syringe. It may come in a pill you take with your morning coffee. Quietly, routinely and for years. That is the promise behind a new partnership between diabetes care pioneer Novo Nordisk and Boston-based biotech Vivtex, a deal valued at up to $2.1 billion that aims to transform injectable obesity and diabetes medicines into oral therapies. The partnership is a classic big-pharma-meets-startup story. But if we look closer, it signals that the obesity…

Credit: Tetiana Marchenko/Getty Images A University of California San Francisco study looking at links between rare monogenic diseases and levels of vitamin B2 and B3 has uncovered a previously unknown link between levels of vitamin B3 and NAXD disease, a very rare, severe metabolic brain disorder of early childhood. As reported in Cell, the study shows how specific vitamins could be used as targeted treatments for rare genetic diseases. The researchers also emphasize that the method of widely screening for diseases linked to vitamin B could be applied to many other vitamins and nutrients. “Among dietary factors, vitamins are uniquely…

Map of millions of oligodendrocytes in the brain of a mouse. [Yu Kang T. Xu and Dwight Bergles, Johns Hopkins Medicine] Researchers headed by a team at Johns Hopkins School of Medicine have used 3D imaging, special microscopes, and artificial intelligence (AI) to construct maps that show the precise location of more than 10 million oligodendrocytes and assess myelin density in mouse brains. The new maps help to paint a whole-brain picture of how myelin content varies between brain circuits, and also provide insight into how the loss of oligodendrocytes impacts human diseases such as multiple sclerosis (MS), Alzheimer’s disease,…

Investment signals shift toward biochemical monitoring in consumer health, performance and preventative care markets. Seveno Capital has announced an investment in PointFit, a Hong Kong-based medtech company developing a next-generation wearable patch designed to continuously monitor biomarkers through sweat. The deal marks another step in Seveno’s strategy of backing technologies that sit at the intersection of performance, prevention and longevity – areas where consumer hardware is increasingly converging with clinical-grade ambition. PointFit’s platform centers on a flexible skin-adherent patch capable of real-time lactate monitoring, with plans to expand into additional sweat-based biomarkers. Positioned initially toward endurance athletes and high-performance users,…

The Gut Microbiota for Health acknowledges the release of the 2025-2030 Dietary Guidelines for Americans. Many recommendations align with longstanding nutrition science, including increased attention to fiber and microbiome health. However, leading nutrition groups (including Harvard T.H. Chan School of Public Health and Stanford Medicine) highlight that the new guidelines deviated notably from the Dietary Guidelines Advisory Committee’s evidence-based recommendations, which may hinder actionable insights for clinicians and nutrition policymakers. Ultimately, this may lead to nutrition decisions by the general public and patients vulnerable to political and food industry influence1,2. The new guidelines offered limited nuance and clarity on how…

Credit: Juanmonino / Getty Images Small, non-coding RNAs that regulate gene expression but are not translated into proteins could affect the lifespan of older people, research suggests. The epigenetic factors, which modulate gene expression without altering the underlying DNA sequence, could one day act as promising biomarkers and therapeutic targets that extend longevity. Blood levels of nine piwi-interacting (pi)RNAs—the largest class of small, non-coding RNAs in animal cells—were all reduced among individuals who lived longer in the study, according to the findings in Aging Cell. Other small, non-coding RNAs called micro (mi)RNAs,—which are just 22 nucleotides in length on average—were…

Beam Therapeutics expanded its liver-targeted genetic disease technology with a new program, BEAM-304, for the treatment of phenylketonuria (PKU), a disease with significant unmet need that affects approximately 20,000 individuals in the U.S. The company also signed a $500 million strategic financing agreement with Sixth Street to fund the potential launch of ristoglogene autogetemcel (risto-cel) in sickle cell disease (SCD). Beam’s newest liver-targeted genetic disease program, BEAM-304, leverages Beam’s proprietary and clinically validated base editing technology and lipid nanoparticle (LNP) delivery capabilities to correct mutations in the phenylalanine hydroxylase (PAH) gene that cause PKU, according to company officials. PKU is…

Mutations in KRAS lead to cancer. Shown here as an example is an illustration of the KRAS G12C mutant oncogene product (center) among red and white blood cells. The G12C mutation is found in a third of lung, and half of colorectal and pancreatic cancers. [Nemes Laszlo/Science Photo Library/Getty Images] Cancer-driving proteins like MYC and KRAS have long evaded even the most sophisticated drug designs, slipping past small molecules and antibodies that struggle to latch onto their surfaces. Now, researchers at Northwestern University have engineered a new way to eliminate these elusive targets entirely: a protein‑like polymer (PLP) that grabs…

Healthtech firm to co-lead scientific program for Women’s Health Summit at London’s June 2026 longevity event. The Longevity Show has confirmed Hertility as Strategic Content and Scientific Lead Partner for the Women’s Health Summit at its inaugural 2026 event in London. The Summit will form a central pillar of the two-day gathering at Tobacco Dock, which aims to convene 4,000 consumers alongside more than 500 clinicians, founders, investors and policymakers working across preventative health and healthspan innovation. Hertility, a UK-based women’s healthtech company focused on reproductive and gynecological diagnostics, telemedicine and AI-enabled precision medicine, will co-lead the scientific framing and…